NURIX THERAPEUTICS, INC. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings
NURIX THERAPEUTICS, INC. (NRIX) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings of $0 for the 3-month period ending 2021-08-31, per its 10-Q filed 2021-10-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings · last filed 2021-10-14
- NURIX THERAPEUTICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2021-08-31 was $0.00.
- NURIX THERAPEUTICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2021-05-31 was $0.00.
- NURIX THERAPEUTICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2021-02-28 was $0.00.
- NURIX THERAPEUTICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for the quarter ending 2020-11-30 was $0.00.
- NURIX THERAPEUTICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale, recognized in earnings for fiscal 2019 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings 12 month |
|---|---|---|---|---|
| 2021-08-31 | $0.00 10-Q · filed 2021-10-14 | $0.00 derived: sum of 2 quarters · filed 2021-10-14 | $0.00 10-Q · filed 2021-10-14 | $0.00 derived: sum of 4 quarters · filed 2021-10-14 |
| 2021-05-31 | $0.00 10-Q · filed 2021-07-13 | $0.00 10-Q · filed 2021-07-13 | $0.00 derived: sum of 3 quarters · filed 2021-07-13 | $0.00 derived: sum of 4 quarters · filed 2021-10-14 |
| 2021-02-28 | $0.00 10-Q · filed 2021-04-13 | $0.00 derived: sum of 2 quarters · filed 2021-04-13 | $0.00 derived: sum of 3 quarters · filed 2021-10-14 | |
| 2020-11-30 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2021-04-13 | $0.00 derived: sum of 2 quarters · filed 2021-10-14 | $0.00 10-Q · filed 2021-04-13 | |
| 2020-08-31 | $0.00 10-Q · filed 2021-10-14 | $0.00 10-Q · filed 2021-10-14 | ||
| 2019-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $0.00 derived: sum of 2 quarters · filed 2021-02-16 | $0.00 10-K · filed 2021-02-16 | |
| 2019-08-31 | $0.00 10-Q · filed 2020-10-14 | |||
| 2019-08-30 | $0.00 10-Q · filed 2020-10-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |